Detalhe da pesquisa
1.
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort.
J Am Acad Dermatol
; 86(2): 345-352, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34153388
2.
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).
Front Oncol
; 13: 1250026, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37936607
3.
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
JCO Precis Oncol
; 6: e2200075, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36356284
4.
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.
Cancers (Basel)
; 12(9)2020 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32947841
5.
Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study.
Cancers (Basel)
; 12(6)2020 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32585901